ArticleJournal of the Egyptian National Cancer Institute2025
Prognostic value of tumor budding in muscle-invasive urothelial carcinoma of the bladder.
Article in Journal of the Egyptian National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder cancer is a common malignancy of the urogenital tract worldwide. Almost 20–30% of new cases are muscle-invasive, a complex pathology with significant clinical and biological variability. Despite treatment advances, predicting disease progression remains challenging due to the limitations of traditional prognostic factors. Identifying new markers, such as tumor budding (TB), could offer a promising breakthrough. The aim of this study was to evaluate TB in muscle-invasive urothelial carcinoma (UC) of the bladder and assess its clinicopathological and prognostic significance.
methodsWe conducted a cross-sectional analytical study of 84 cases of muscle-invasive UC of the bladder. TB was assessed based on the 2016 International Tumor Budding Consensus Conference guidelines and correlated with clinicopathological features and patient survival.
resultsThe study included 77 men and 7 women, with a mean age of 68.13 ± 9.41 years. Histologically, ulcerative proliferative and infiltrative features were most common (58%), and high-grade tumors accounted for 92.9% of cases. Tumors were mainly classified as pT4a (40.5%), with lymph node metastasis observed in 34.3%. The mean overall survival was 23.07 ± 1.9 months. TB was present in 41.7% of cases, with Bd1 in 9.5%, Bd2 in 16.7%, and Bd3 in 15.5% of UCs. Significant correlations were found between TB and the pattern of the invasive front (p = 0.002), presence of carcinoma in situ component (p = 0.024), vascular emboli (p = 0.020), lymphatic emboli (p = 0.044), perineural invasion (p = 0.012), and parietal wall infiltration (p = 0.006).
conclusionThese findings suggest that TB serves as an independent histoprognostic predictor of the aggressiveness of muscle-invasive UC, warranting its inclusion in pathology reports and treatment protocols. However, to further validate these findings, large-scale prospective studies with standardized methods for evaluating TB are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.